Hyperbaric Oxygen Shows Promise for Treating Deadly Brain Tumors

Brain tumors represent some of the most challenging cancers to treat, with glioblastomas showing particularly poor prognosis despite aggressive treatment. This review explores how hyperbaric oxygen therapy (HBOT) could revolutionize treatment outcomes by addressing a fundamental problem: tumor hypoxia.

The research examined multiple studies involving patients with gliomas and brain metastases who received HBOT combined with radiotherapy. HBOT involves placing patients in pressurized chambers where they breathe pure oxygen at 1.5-2.5 times atmospheric pressure. This dramatically increases oxygen levels in both normal and tumor tissues by 100-115%, directly addressing the hypoxic conditions that make tumors resistant to radiation.

Key clinical trials showed promising results. In one study of 80 glioblastoma patients, those receiving HBOT with radiotherapy had an 18-month survival rate of 28% versus 10% for controls, with median survival extending from 31 to 38 weeks. Another study of 57 patients achieved a median overall survival of 20.2 months, with glioblastoma patients surviving 17.2 months compared to historical controls.

Beyond survival benefits, HBOT appears to protect against radiation-induced brain damage. The therapy promotes blood vessel growth through VEGF pathways and reduces inflammatory responses that contribute to radiation necrosis. Studies combining HBOT with stereotactic radiosurgery for brain metastases showed the approach was both feasible and safe.

While results are encouraging, most studies were small and lacked randomized controlled designs. The optimal timing, pressure levels, and patient selection criteria require further investigation through larger clinical trials.